Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Eli Lilly & Co. (LLY), AstraZeneca (AZN) Extend Immuno-Oncology Collaboration
October 22, 2015 6:21 AM EDTEli Lilly & Co. (NYSE: LLY) and AstraZeneca (NYSE: AZN) announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.
Under the terms of the expanded agreement, Lilly and AstraZeneca will evaluate the safety and efficacy of a range of additional combinations across the companies' complementary portfolios. Lilly will lead the execution of the studies, while both companies will contribute resources. Additional... More
